YMN-V112

YMN-V112 is a recombinant humanized monoclonal antibody targeting the CD19 antigen, currently under development by West China Hospital of Sichuan University. It is designed for the treatment of autoimmune diseases, specifically active rheumatoid arthritis (RA), by inducing the depletion of B-lymphocytes. B-cells are key drivers of inflammation in RA, contributing to the production of autoantibodies (such as rheumatoid factor and anti-citrullinated protein antibodies) and pro-inflammatory cytokines. YMN-V112 is currently being evaluated in a Phase 1, single-cohort, dose-escalation study utilizing a 3+3 design to assess its safety, tolerability, and preliminary efficacy in adults with active RA who have had an inadequate response to prior disease-modifying antirheumatic drugs (DMARDs). The drug is administered via intravenous infusion.